bendroflumethiazide has been researched along with Diabetes Mellitus, Type 1 in 4 studies
Bendroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810)
bendroflumethiazide : A sulfonamide consisting of 7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by a trifluoromethyl group and that at position 3 is substituted by a benzyl group.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Captopril is a valuable new drug for treating hypertension in insulin dependent diabetics with nephropathy." | 6.66 | Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. ( Hommel, E; Parving, HH; Smidt, UM, 1988) |
| "Captopril is a valuable new drug for treating hypertension in insulin dependent diabetics with nephropathy." | 2.66 | Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. ( Hommel, E; Parving, HH; Smidt, UM, 1988) |
| "Eighteen hypertensive IDDM patients with diabetic nephropathy, who had not been treated previously, were followed during 3 years of treatment with captopril and frusemide or bendrofluazide." | 1.29 | Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. ( Hommel, E; Parving, HH; Rossing, P; Smidt, UM, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Parving, HH | 4 |
| Rossing, P | 2 |
| Hommel, E | 4 |
| Smidt, UM | 3 |
| Larsen, M | 1 |
| Lund-Andersen, H | 1 |
2 trials available for bendroflumethiazide and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Bendroflumethiazide; Blood Pressure; C | 1995 |
Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy.
Topics: Adult; Albuminuria; Bendroflumethiazide; Captopril; Clinical Trials as Topic; Diabetes Mellitus, Typ | 1988 |
2 other studies available for bendroflumethiazide and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment.
Topics: Adult; Albuminuria; Antihypertensive Agents; Bendroflumethiazide; Blood Pressure; Captopril; Diabete | 1994 |
Effect of antihypertensive treatment on blood-retinal barrier permeability to fluorescein in hypertensive type 1 (insulin-dependent) diabetic patients with background retinopathy.
Topics: Adult; Albuminuria; Bendroflumethiazide; Blood Glucose; Blood Pressure; Blood-Retinal Barrier; Capto | 1989 |